Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,450 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
U.S. Food and Drug Administration approval: panitumumab for epidermal growth factor receptor-expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.
Giusti RM, Shastri K, Pilaro AM, Fuchs C, Cordoba-Rodriguez R, Koti K, Rothmann M, Men AY, Zhao H, Hughes M, Keegan P, Weiss KD, Pazdur R. Giusti RM, et al. Among authors: fuchs c. Clin Cancer Res. 2008 Mar 1;14(5):1296-302. doi: 10.1158/1078-0432.CCR-07-1354. Clin Cancer Res. 2008. PMID: 18316547 Clinical Trial.
Approval summary: Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil for the first-line treatment of patients with recurrent locoregional or metastatic squamous cell head and neck cancer.
Cohen MH, Chen H, Shord S, Fuchs C, He K, Zhao H, Sickafuse S, Keegan P, Pazdur R. Cohen MH, et al. Among authors: fuchs c. Oncologist. 2013;18(4):460-6. doi: 10.1634/theoncologist.2012-0458. Epub 2013 Apr 10. Oncologist. 2013. PMID: 23576486 Free PMC article.
FDA's Approval of the First Biosimilar to Bevacizumab.
Casak SJ, Lemery SJ, Chung J, Fuchs C, Schrieber SJ, Chow ECY, Yuan W, Rodriguez L, Gwise T, Rowzee A, Lim S, Keegan P, McKee AE, Pazdur R. Casak SJ, et al. Among authors: fuchs c. Clin Cancer Res. 2018 Sep 15;24(18):4365-4370. doi: 10.1158/1078-0432.CCR-18-0566. Epub 2018 May 9. Clin Cancer Res. 2018. PMID: 29743182
Role of risk assessments in viral safety: an FDA perspective.
Xu L, Lee SB, Fuchs C, Hyams KC, Brorson K, Swann P. Xu L, et al. Among authors: fuchs c. PDA J Pharm Sci Technol. 2014 Jan-Feb;68(1):6-10. doi: 10.5731/pdajpst.2014.00959. PDA J Pharm Sci Technol. 2014. PMID: 24504229 No abstract available.
An autocrine synergistic desmin-SPARC network promotes cardiomyogenesis in cardiac stem cells.
Leitner L, Schultheis M, Hofstetter F, Rudolf C, Fuchs C, Kizner V, Fiedler K, Konrad MT, Höbaus J, Genini M, Kober J, Ableitner E, Gmaschitz T, Walder D, Weitzer G. Leitner L, et al. Among authors: fuchs c. Cells Dev. 2024 Dec 27:203990. doi: 10.1016/j.cdev.2024.203990. Online ahead of print. Cells Dev. 2024. PMID: 39734020 Free article.
Summary of the 2024 Professionals in Nutrition for Exercise and Sport "10 Questions/10 Experts" Session-Hot Topics for the Paris Olympic Games.
Wardenaar FC, Clark N, Stellingwerff T, Siegler J, Saunders B, Dolan E, Wilson PB, Hawley JA, Fuchs CJ, Aussieker T, Phillips SM, Manore M, Burke LM. Wardenaar FC, et al. Among authors: fuchs cj. Int J Sport Nutr Exerc Metab. 2024 Nov 13;35(1):76-83. doi: 10.1123/ijsnem.2024-0167. Print 2025 Jan 1. Int J Sport Nutr Exerc Metab. 2024. PMID: 39560956
1,450 results